TScan Therapeutics, Inc. Common Stock (TCRX) is a publicly traded Healthcare sector company. As of September 30, 2026, TCRX trades at $0.32 with a market cap of $21.52M and a P/E ratio of -0.36. TCRX moved +0.79% today. Year to date, TCRX is -69.17%; over the trailing twelve months it is -82.72%. Its 52-week range spans $0.29 to $2.57. Analyst consensus is neutral with an average price target of $1.00. Rallies surfaces TCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks TCRX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $0.32 |
| Market Cap | $21.52M |
| P/E Ratio | -0.36 |
| EPS | $-0.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.57 |
| 52-Week Low | $0.29 |
| Volume | 533.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.11M |
| Net Income | $-117.71M |
| Gross Margin | 0.00% |
6 analysts cover TCRX: 0 strong buy, 1 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $1.00.